23 July 2014 – PLC congratulates Lightlake Therapeutics on for their recent IND filing for a naloxone-based opioid overdose reversal nasal spray. PLC has worked with Lightlake on their regulatory pathway strategy for approval of this drug product and filed the IND application behalf of Lightlake.
Lightlake Therapeutics Inc. Files Investigational NDA For Naloxone Nasal Spray For Reversing Opioid Overdose
